Consistent effect of empagliflozin on composite outcomes related to heart failure: results from EMPA-REG OUTCOME

被引：0
|
作者：
Schnee, J. [1 ]
Inzucchi, S. E. [2 ]
Zinman, B. [3 ,4 ]
McGinniss, J. [1 ]
George, J. T. [5 ]
Fitchett, D. [6 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
[3] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[4] Univ Toronto, Div Endocrinol, Toronto, ON, Canada
[5] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[6] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
182
引用
收藏
页码：S85 / S86
页数：2
相关论文
共 50 条
  • [1] CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Zinman, Bernard
    McGinniss, Jennifer
    Schnee, Janet
    George, Jyothis
    Fitchett, David
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 1656 - 1656
  • [2] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. J.
    Inzucchi, S. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
  • [3] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
    Monteiro, Pedro
    Schaper, Nicolaas
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    DIABETES, 2016, 65 : A291 - A291
  • [4] EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    Lee, Dae Wook
    Monteiro, Pedro
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    JOURNAL OF HYPERTENSION, 2016, 34 : E520 - E520
  • [5] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. -J.
    Inzucchi, S. E.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S534 - S534
  • [6] Mediators of the Improvement in Heart Failure Outcomes With Empagliflozin in the EMPA-REG OUTCOME Trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Zannad, Faiez
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    CIRCULATION, 2017, 136
  • [7] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Ofstad, Anne Pernille
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    Zannad, Faiez
    ESC HEART FAILURE, 2021, 8 (06): : 4517 - 4527
  • [8] Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David
    Inzucchi, Silvio E.
    Zinman, Bernard
    Wanner, Christoph
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Ofstad, Anne Pernille
    Salsali, Afshin
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    Zannad, Faiez
    ESC HEART FAILURE, 2022, 8 (06): : 4517 - 4527
  • [9] Empagliflozin and Microvascular Outcomes in EMPA-REG Outcome
    Wanner, Christoph
    Lee, Christopher
    Woerle, Hans J.
    Mattheus, Michaela
    Inzucchi, Silvio E.
    Zinman, Bernard
    DIABETES, 2016, 65 : A283 - A283
  • [10] Empagliflozin and microvascular outcomes in EMPA-REG OUTCOME
    Wanner, C.
    Lee, C.
    Woerle, H. -J.
    Mattheus, M.
    Inzucchi, S. E.
    Zinman, B.
    DIABETOLOGIA, 2016, 59 : S483 - S484
12345